| 1. |
Kirsner, J.B. (2001) Historical origins of current IBD concepts. World J Gastroenterol 7, 175–184
|
| |
| 2. |
Crohn, B.B., Ginzburg, L., Oppenheimer, G.D. (2000) Regional ileitis: a pathologic and clinical entity. 1932. Mt Sinai J Med 67, 263–268
|
| |
| 3. |
Balkwill, F., Mantovani, A. (2001) Inflammation and cancer: back to Virchow? Lancet 357, 539–545
|
| |
| 4. |
Coussens, L.M., Werb, Z. (2002) Inflammation and cancer. Nature 420, 860–867
|
| |
| 5. |
Fuss, I.J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., Yang, Z., Exley, M., Kitani A., Blumberg,
R.S., Mannon, P., Strober, W. (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2
response in ulcerative colitis. J Clin Invest 113, 1490–1497
|
| |
| 6. |
Kewenter, J., Ahlman, H., Hulten, L. (1978) Cancer risk in extensive ulcerative colitis. Ann Surg 188, 824–828
|
| |
| 7. |
Prior, P., Gyde, S.N., Macartney, J.C., Thompson, H., Waterhouse, J.A., Allan, R.N. (1982) Cancer morbidity in ulcerative
colitis. Gut 23, 490–497
|
| |
| 8. |
Brostrom, O., Löfberg, R., Nordenvall, B., Ost, A., Hellers, G. (1987) The risk of colorectal cancer in ulcerative colitis.
An epi-demiologic study. Scand J Gastroenterol 22, 1193–1199
|
| |
| 9. |
Ekbom, A., Helmick, C., Zack, M., Adami, H.O. (1990) Ulcerative colitis and colorec-tal cancer. A population-based study.
N Engl J Med 323, 1228–1233
|
| |
| 10. |
Lashner, B.A., Silverstein, M.D., Hanauer, S.B. (1989) Hazard rates for dysplasia and cancer in ulcerative colitis. Results
from a surveillance program. Dig Dis Sci 34, 1536– 1541
|
| |
| 11. |
Sugita, A., Sachar, D.B., Bodian, C., Ribeiro, M.B., Aufses, A.H., Jr. Greenstein, A.J. (1991) Colorectal cancer in ulcerative
colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 32, 167–169
|
| |
| 12. |
Eaden, J.A., Abramsb, K.R., Mayberry, J.F. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526–535
|
| |
| 13. |
Chen, R., Rabinovitch, P.S., Crispin, D.A., Emond, M.J., Koprowicz, K.M., Bronner, M.P., Brentnall, T.A. (2003) DNA fingerprinting
abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.
Am J Pathol 162, 665–672
|
| |
| 14. |
Greenson, J.K. (2002) Dysplasia in inflammatory bowel disease. Semin Diagn Pathol 19, 31–37
|
| |
| 15. |
Sartor, R.B. (1995) Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 24, 475–507
|
| |
| 16. |
Fiocchi, C. (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroen-terology 115, 182–205
|
| |
| 17. |
Bouma, G., Strober, W. (2003) The immu-nological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3, 521– 533
|
| |
| 18. |
Yang, H., McElree, C., Roth, M.P., Shana-han, F., Targan, S.R., Rotter, J.I. (1993) Familial empirical risks for inflammatory
bowel disease: differences between Jews and non-Jews. Gut 34, 517–524
|
| |
| 19. |
Tysk, C., Lindberg, E., Järnerot, G., Floderus-Myrhed, B. (1988) Ulcerative colitis and Crohn's disease in an unselected population
of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29, 990–996
|
| |
| 20. |
Hampe, J., Cuthbert, A., Croucher, P.J., Mirza, M.M., Mascheretti, S., Fisher, S., Frenzel, H., King, K., Hasselmeyer, A.,
MacPherson, A.J., Bridger, S., van Deventer, S., Forbes, A., Nikolaus, S., Lennard-Jones, J.E., Foelsch, U.R., Krawczak, M.,
Lewis, C., Schreiber, S., Mathew, C.G. (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German
and British populations. Lancet 357, 1925–1928
|
| |
| 21. |
Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cezard, J.P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C.A., Gas-sull,
M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J.F., Sahbatou,
M., Thomas, G. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599–603
|
| |
| 22. |
Ogura, Y., Bonen, D.K., Inohara, N., Nico-lae, D.L., Chen, F.F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr,
R.H., Achkar, J.P., Brant, S.R., Bayless, T.M., Kirschner, B.S., Hanauer, S.B., Nunez, G., Cho, J.H. (2001) A frameshift mutation
in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603–606
|
| |
| 23. |
Ogura, Y., Inohara, N., Benito, A., Chen, F.F., Yamaoka, S., Nunez, G. (2001) Nod2, a Nod1/Apaf-1 family member that is restricted
to monocytes and activates NF-kappaB. J Biol Chem 276, 4812–4818
|
| |
| 24. |
Abreu, M.T., Taylor, K.D., Lin, Y.C., Hang, T., Gaiennie, J., Landers, C.J., Vasiliauskas, E.A., Kam, L.Y., Rojany, M., Papadakis,
K.A., Rotter, J.I., Targan, S.R., Yang, H. (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients
with Crohn's disease. Gastroenterology 123, 679–688
|
| |
| 25. |
Maeda, S., Hsu, L.C., Liu, H., Bankston, L.A., Iimura, M., Kagnoff, M.F., Eckmann, L., Karin, M. (2005) Nod2 mutation in Crohn's
disease potentiates NF-kappaB activity and IL-1beta processing. Science 307, 734–738
|
| |
| 26. |
Kobayashi, K., Inohara, N., Hernandez, L.D., Galan, J.E., Nunez, G., Janeway, C.A., Medzhitov, R., Flavell, R.A. (2002) RICK/Rip2/CARDIAK
mediates signalling for receptors of the innate and adaptive immune systems. Nature 416, 194–199
|
| |
| 27. |
Satsangi, J., Morecroft, J., Shah, N.B., Nimmo, E. (2003) Genetics of inflammatory bowel disease: scientific and clinical
implications. Best Pract Res Clin Gastroen-terol 17, 3–18
|
| |
| 28. |
Duerr, R.H., Taylor, K.D., Brant, S.R., Rioux, J.D., Silverberg, M.S., Daly, M.J., Steinhart, A.H., Abraham, C., Regueiro,
M., Griffiths, A., Dassopoulos, T., Bitton, A., Yang, H., Targan, S., Datta, L.W., Kistner, E.O., Schumm, L.P., Lee, A.T.,
Gregersen, P.K., Barmada, M.M., Rotter, J.I., Nicolae, D.L., Cho, J.H. (2006) A genome-wide association study identifies IL23R
as an inflammatory bowel disease gene. Science 314, 1461–1463
|
| |
| 29. |
Satsangi, J., Parkes, M., Louis, E., Hashimoto, L., Kato, N., Welsh, K., Terwilliger, J.D., Lathrop, G.M., Bell, J.I., Jewell,
D.P. (1996) Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes
3, 7 and 12. Nat Genet 14, 199–202
|
| |
| 30. |
Peltekova, V.D., Wintle, R.F., Rubin, L.A., Amos, C.I., Huang, Q., Gu, X., Newman, B., Van Oene, M., Cescon, D., Greenberg,
G., Griffiths, A.M., St George-Hyslop, P.H., Siminovitch, K.A. (2004) Functional variants of OCTN cation transporter genes
are associated with Crohn disease. Nat Genet 36, 471–475
|
| |
| 31. |
Toyoda, H., Wang, S.J., Yang, H.Y., Red-ford, A., Magalong, D., Tyan, D., McElree, C.K., Pressman, S.R., Shanahan, F., Targan,
S.R., et al. (1993) Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 104, 741–748
|
| |
| 32. |
Asquith, P., Mackintosh, P., Stokes, P.L., Holmes, G.K., Cooke, W.T. (1974) His-tocompatibility antigens in patients with
inflammatory-bowel disease. Lancet 1, 113– 115
|
| |
| 33. |
Strober, W., Fuss, I.J., Blumberg, R.S. (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20, 495–549
|
| |
| 34. |
Savidge, T.C., Newman, P.G., Pan, W.H., Weng, M.Q., Shi, H.N., McCormick, B.A., Quaroni, A., Walker, W.A. (2006) Lipopol-ysaccharide-induced
human enterocyte tolerance to cytokine-mediated interleukin-8 production may occur independently of TLR-4/MD-2 signaling.
Pediatr Res 59, 89–95
|
| |
| 35. |
de Baey, A., Memde, I., Baretton, G., Greiner, A., Hartl, W.H., Baeuerle, P.A., Diepolder, H.M. (2003) A subset of human dendritic
cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol 170, 5089–5094
|
| |
| 36. |
Parronchi, P., Romagnani, P., Annunziato, F., Sampognaro, S., Becchio, A., Gian-narini, L., Maggi, E., Pupilli, C., Tonelli,
F., Romagnani, S. (1997) Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's
disease. Am J Pathol 150, 823–832
|
| |
| 37. |
Brown, S.J., Mayer, L. (2007) The immune response in inflammatory bowel disease. Am J Gastroenterol, 102, 2058–2069
|
| |
| 38. |
Nikolaus, S., Bauditz, J., Gionchetti, P., Witt, C., Lochs, H., Schreiber, S. (1998) Increased secretion of pro-inflammatory
cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 42, 470–476
|
| |
| 39. |
Tyrer, P., Foxwell, A.R. Cripps, A.W. Api-cella, M.A. Kyd, J.M. (2006) Microbial pattern recognition receptors mediate M-cell
uptake of a gram-negative bacterium. Infect Immun 74, 625–631
|
| |
| 40. |
Lodes, M.J., Cong, Y., Elson, C.O., Mohamath, R., Landers, C.J., Targan, S.R., Fort, M., Hershberg, R.M. (2004) Bacterial
flagellin is a dominant antigen in Crohn disease. J Clin Invest 113, 1296–1306
|
| |
| 41. |
Rakoff-Nahoum, S., Paglino, J., Eslami-Var-zaneh, F., Edberg, S., Medzhitov, R. (2004) Recognition of commensal microflora
by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241
|
| |
| 42. |
Fukata, M., Michelsen, K.S., Eri, R., Thomas, L.S., Hu, B., Lukasek, K., Nast, C.C., Lechago, J., Xu, R., Naiki, Y., Soliman,
A., Arditi, M., Abreu, M.T. (2005) Tolllike receptor-4 is required for intestinal response to epithelial injury and limiting
bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288, G1055–1065
|
| |
| 43. |
Doering, J., Begue, B., Lentze, M.J., Rieux-Laucat, F., Goulet, O., Schmitz, J. Cerf-Bensussan, N., Ruemmele, F.M. (2004)
Induction of T lymphocyte apoptosis by sul-phasalazine in patients with Crohn's disease. Gut 53, 1632–1638
|
| |
| 44. |
Mosmann, T.R., Cher winski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L. (1986) Two types of murine helper T cell clone. I.
Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348–2357
|
| |
| 45. |
Mannon, P.J., Fuss, I.J. Mayer, L., Elson, C.O., Sandborn, W.J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung,
R.L., Quezado, M., Yang, Z., Neurath, M.F., Salfeld, J., Veldman, G.M., Schwertschlag, U., Strober, W. (2004) Anti-interleukin-12
antibody for active Crohn's disease. N Engl J Med 351, 2069–2079
|
| |
| 46. |
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., Fujiyama, Y. (2003) Increased expression of interleukin
17 in inflammatory bowel disease. Gut 52, 65–70
|
| |
| 47. |
Niessner, M., Volk, B.A. (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel
disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101, 428–435
|
| |
| 48. |
MacDonald, T.T., Pender, S.L. (1998) Lamina propria T cells. Chem Immunol 71, 103–117
|
| |
| 49. |
Fuss, I.J., Neurath, M., Boirivant, M., Klein, J.S., de la Motte, C., Strong, S.A., Fiocchi, C., Strober, W. (1996) Disparate
CD4 + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased
secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157, 1261–1270
|
| |
| 50. |
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T. (2005) Interleukin 17-producing
CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6, 1123–1132
|
| |
| 51. |
Trinchieri, G. (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3, 133–146
|
| |
| 52. |
Davidson, N.J., Hudak, S.A., Lesley, R.E., Menon, S., Leach, M.W., Rennick, D.M. (1998) IL-12, but not IFN-gamma, plays a
major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 161, 3143–3149
|
| |
| 53. |
Fuss, I.J., Becker, C., Yang, Z., Groden, C., Hornung, R.L., Heller, F., Neurath, M.F., Strober, W., Mannon, P.J. (2006) Both
IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal
antibody. Inflamm Bowel Dis 12, 9–15
|
| |
| 54. |
Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Klein-schek, M.A., Owyang, A., Mattson, J.,
Blu-menschein, W., Murphy, E., Sathe, M., Cua, D.J., Kastelein, R.A., Rennick, D. (2006) IL-23 is essential for T cell-mediated
colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116, 1310–1316
|
| |
| 55. |
Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer,
S.B., Lichtenstein, G.R., de Villiers, W.J., Present, D., Sands, B.E., Colombel, J.F. (2005) Infliximab for induction and
maintenance therapy for ulcerative colitis. N Engl J Med 353, 2462–2476
|
| |
| 56. |
Katz, S. (2005) Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 39, 557–569
|
| |
| 57. |
Olson, T.S., Bamias, G., Naganuma, M., Rivera-Nieves, J., Burcin, T.L., Ross, W., Morris, M.A., Pizarro, T.T., Ernst, P.B.,
Cominelli, F., Ley, K. (2004) Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model
of Crohn disease. J Clin Invest 114, 389–398
|
| |
| 58. |
Kawamura, T., Kanai, T., Dohi, T., Uraushi-hara, K., Totsuka, T., Iiyama, R., Taneda, C., Yamazaki, M., Nakamura, T., Higuchi,
T., Aiba, Y., Tsubata, T., Watanabe, M. (2004) Ectopic CD40 ligand expression on B cells triggers intestinal inflammation.
J Immunol 172, 6388–6397
|
| |
| 59. |
Lee, J.C., Cevallos, A.M., Naeem, A., Len-nard-Jones, J.E., Farthing, M.J. (1999) Detection of anti-colon antibodies in inflammatory
bowel disease using human cultured colonic cells. Gut 44, 196–202
|
| |
| 60. |
Das, K.M., Squillante, L., Chitayet, D., Kalousek, D.K. (1992) Simultaneous appearance of a unique common epitope in fetal
colon, skin, and biliary epithelial cells. A possible link for extracolonic manifestations in ulcerative colitis. J Clin Gastroen-terol 15, 311–316
|
| |
| 61. |
Cohavy, O., Bruckner, D., Gordon, L.K., Misra, R., Wei, B., Eggena, M.E., Targan, S.R., Braun, J. (2000) Colonic bacteria
express an ulcerative colitis pANCA-related protein epitope. Infect Immun 68, 1542– 1548
|
| |
| 62. |
Mow, W.S., Vasiliauskas, E.A., Lin, Y.C., Fleshner, P.R., Papadakis, K.A., Taylor, K.D., Landers, C.J., Abreu-Martin, M.T.,
Rotter, J.I., Yang, H., Targan, S.R. (2004) Association of antibody responses to micro-bial antigens and complications of
small bowel Crohn's disease. Gastroenterology 126, 414–424
|
| |
| 63. |
Arnott, I.D., Landers, C.J., Nimmo, E.J., Drummond, H.E., Smith, B.K., Targan, S.R., Satsangi, J. (2004) Sero-reactivity to
microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.
Am J Gastroenterol 99, 2376–2384
|
| |
| 64. |
Lih-Brody, L., Powell, S.R., Collier, K.P., Reddy, G.M., Cerchia, R., Kahn, E., Weiss-man, G.S., Katz, S., Floyd, R.A., McKinley,
M.J., Fisher, S.E., Mullin, G.E. (1996) Increased oxidative stress and decreased anti-oxidant defenses in mucosa of inflammatory
bowel disease. Dig Dis Sci 41, 2078–2086
|
| |
| 65. |
Simmonds, N.J., Allen, R.E. Stevens, T.R., Van Someren, R.N., Blake, D.R., Ramp-ton, D.S. (1992) Chemiluminescence assay of
mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterol-ogy 103, 186–196
|
| |
| 66. |
McKenzie, S.J., Baker, M.S., Buffinton, G.D., Doe, W.F. (1996) Evidence of oxi-dant-induced injury to epithelial cells during
inflammatory bowel disease. J Clin Invest 98, 136–141
|
| |
| 67. |
Mahida, Y.R., Wu, K.C. Jewell, D.P. (1989) Respiratory burst activity of intestinal macrophages in normal and inflammatory
bowel disease. Gut 30, 1362–1370
|
| |
| 68. |
Schreiber, S., MacDermott, R.P., Raedler, A., Pinnau, R., Bertovich, M.J., and Nash, G.S. (1991) Increased activation of isolated
intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenter-ology 101, 1020–1030
|
| |
| 69. |
Babbs, C.F. (1992) Oxygen radicals in ulcerative colitis. Free Radic Biol Med 13, 169–181
|
| |
| 70. |
Grisham, M.B. (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344, 859–861
|
| |
| 71. |
Hussain, S.P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W.P., Shields, P.G., Ham, A.J., Swenberg, J.A., Marrogi,
A.J., Harris, C.C. (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone
chronic inflammatory disease. Cancer Res 60, 3333–3337
|
| |
| 72. |
Hisamatsu, T., Watanabe, M., Ogata, H., Ezaki, T., Hozawa, S., Ishii, H., Kanai, T., Hibi, T. (1999) Interferon-inducible
gene family 1–8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res 59, 5927–5931
|
| |
| 73. |
Oudkerk Pool, M., Bouma, G., Visser, J.J., Kolkman, J.J., Tran, D.D., Meuwissen, S.G., Pena, A.S. (1995) Serum nitrate levels
in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 30, 784–788
|
| |
| 74. |
Rachmilewitz, D., Stamler, J.S., Bachwich, D., Karmeli, F., Ackerman, Z., Podolsky, D.K. (1995) Enhanced colonic nitric oxide
generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 36, 718–723
|
| |
| 75. |
Hofseth, L.J., Shinichi, S., Hussain, S.P., Espey, M.G., Miranda, K.M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke,
S.P., Quezado, M.M., Zurer, I., Rotter, V., Wink, D.A., Appella, E., Harris, C.C. (2003) Nitric oxide-induced cellular stress
and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100, 143–148
|
| |
| 76. |
Kimura, H., Hokari, R., Miura, S., Shige-matsu, T., Hirokawa, M., Akiba, Y., Kurose, I., Higuchi, H., Fujimori, H., Tsuzuki,
Y., Serizawa, H., Ishii, H. (1998) Increased expression of an inducible isoform of nitric oxide synthase and the formation
of perox-ynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42, 180–187
|
| |
| 77. |
Kimura, H., Miura, S., Shigematsu, T., Ohkubo, N., Tsuzuki, Y., Kurose, I., Higuchi, H., Akiba, Y., Hokari, R., Hirokawa,
M., Serizawa, H., Ishii, H. (1997) Increased nitric oxide production and inducible nitric oxide synthase activity in colonic
mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci 42, 1047–1054
|
| |
| 78. |
Hokari, R., Kato, S., Matsuzaki, K., Kuroki, M., Iwai, A., Kawaguchi, A., Nagao, S., Miyahara, T., Itoh, K., Sekizuka, E.,
Nagata, H., Ishii, H., Miura, S. (2001) Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis.
Free Radic Biol Med 31, 153–163
|
| |
| 79. |
Singer, II, Kawka, D.W., Scott, S., Weidner, J.R., Mumford, R.A., Riehl, T.E., Stenson, W.F. (1996) Expression of inducible
nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111, 871–885
|
| |
| 80. |
Rachmilewitz, D., Stamler, J.S., Karmeli, F., Mullins, M.E., Singel, D.J., Loscalzo, J., Xavier, R.J., Podolsky, D.K. (1993)
Perox-ynitrite-induced rat colitis–a new model of colonic inflammation. Gastroenterology 105, 1681–1688
|
| |
| 81. |
Rogler, G., Brand, K., Vogl, D., Page, S., Hofmeister, R., Andus, T., Knuechel, R., Baeuerle, P.A., Scholmerich, J., Gross,
V. (1998) Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115, 357–369
|
| |
| 82. |
Yamamoto, Y., Gaynor, R.B. (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation
and cancer. J Clin Invest 107, 135–142
|
| |
| 83. |
Dubuquoy, L., Jansson, E.A., Deeb, S., Rakotobe, S., Karoui, M., Colombel, J.F., Auwerx, J., Pettersson, S., Desreumaux, P.
(2003) Impaired expression of peroxi-some proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124, 1265–1276
|
| |
| 84. |
Su, C.G., Wen, X., Bailey, S.T., Jiang, W., Rangwala, S.M., Keilbaugh, S.A., Flani-gan, A., Murthy, S., Lazar, M.A., Wu, G.D.
(1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104, 383–389
|
| |
| 85. |
Dull, B.J., Salata, K., Van Langenhove, A., Goldman, P. (1987) 5-Aminosalicylate: oxidation by activated leukocytes and protection
of cultured cells from oxidative damage. Biochem Pharmacol 36, 2467–2472
|
| |
| 86. |
Craven, P.A., Pfanstiel, J., Saito, R., DeRu-bertis, F.R. (1987) Actions of sulfasalazine and 5-aminosalicylic acid as reactive
oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.
Gastroenterol-ogy 92, 1998–2008
|
| |
| 87. |
Gionchetti, P., Gionchetti, C., Campieri, M., Belluzzi, A., Brignola, C., Iannone, P., Miglioli, M., Barbara, L. (1991) Scavenger
effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 36, 174–178
|
| |
| 88. |
Seril, D.N., Liao, J., Ho, K.L., Warsi, A., Yang, C.S., Yang, G.Y. (2002) Dietary iron supplementation enhances DSS-induced
colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 47, 1266– 1278
|
| |
| 89. |
Keshavarzian, A., Morgan, G., Sedghi, S., Gordon, J.H., Doria, M. (1990) Role of reactive oxygen metabolites in experimental
colitis. Gut 31, 786–790
|
| |
| 90. |
Keshavarzian, A., Haydek, J., Zabihi, R., Doria, M., D'Astice, M., Sorenson, J.R. (1992) Agents capable of eliminating reactive
oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis. Dig Dis Sci 37, 1866–1873
|
| |
| 91. |
Rachmilewitz, D., Karmeli, F., Okon, E., Bursztyn, M. (1995) Experimental colitis is ameliorated by inhibition of nitric oxide
synthase activity. Gut 37, 247–255
|
| |
| 92. |
Naito, Y., Takagi, T. Ishikawa, T. Handa, O. Matsumoto, N. Yagi, N. Matsuyama, K. Yoshida, N. Yoshikawa, T. (2001) The inducible
nitric oxide synthase inhibitor ONO-1714 blunts dextran sulfate sodium colitis in mice. Eur J Pharmacol 412, 91–99
|
| |
| 93. |
Seril, D.N., Liao, J., Yang, G.Y., Yang, C.S. (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies
in humans and animal models. Carcinogenesis 24, 353–362
|
| |
| 94. |
Chu, F.F., Esworthy, R.S., Chu, P.G., Long-mate, J.A., Huycke, M.M., Wilczynski, S., Doroshow, J.H. (2004) Bacteria-induced
intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 64, 962– 968
|
| |
| 95. |
Buffinton, G.D., Doe, W.F. (1995) Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med 19, 911–918
|
| |
| 96. |
Holmes, E.W., Yong, S.L., Eiznhamer, D., Keshavarzian, A. (1998) Glutathione content of colonic mucosa: evidence for oxida-tive
damage in active ulcerative colitis. Dig Dis Sci 43, 1088–1095
|
| |
| 97. |
Ekbom, A., Adami, H.O., Helmick, C.G., Jonzon, A., Zack, M.M. (1990) Perinatal risk factors for inflammatory bowel disease:
a case-control study. Am J Epidemiol 132, 1111–1119
|
| |
| 98. |
Russel, M.G., Stockbrugger, R.W. (1996) Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 31, 417–427
|
| |
| 99. |
Dejaco, C., Harrer, M., Waldhoer, T., Miehsler, W., Vogelsang, H., Reinisch, W. (2003) Antibiotics and azathioprine for the
treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 18, 1113– 1120
|
| |
| 100. |
Wild, G.E. (2004) The role of antibiotics in the management of Crohn's disease. Inflamm Bowel Dis 10, 321–323
|
| |
| 101. |
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., Kerremans, R. (1995) Controlled trial of metronidazole
treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108, 1617–1621
|
| |
| 102. |
Rutgeerts, P., Van Assche, G., Vermeire, S., D'Haens, G., Baert, F., Noman, M., Aer-den, I., De Hertogh, G., Geboes, K., Hiele,
M., D'Hoore, A., Penninckx, F. (2005) Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized,
double-blind, placebo-controlled trial. Gas-troenterology 128, 856–861
|
| |
| 103. |
Auer, I.O., Roder, A., Wensinck, F., van de Merwe, J.P., Schmidt, H. (1983) Selected bacterial antibodies in Crohn's disease
and ulcerative colitis. Scand J Gastroenterol 18, 217–223
|
| |
| 104. |
Duchmann, R., Schmitt, E., Knolle, P., Meyer zum Buschenfelde, K.H., Neurath, M. (1996) Tolerance towards resident intestinal
flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to inter-leukin-12.
Eur J Immunol 26, 934–938
|
| |
| 105. |
Burke, D.A., Axon, A.T. (1987) Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol 40, 782–786
|
| |
| 106. |
Roediger, W.E., Moore, J., Babidge, W. (1997) Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 42, 1571–1579
|
| |
| 107. |
Levine, J., Ellis, C.J., Furne, J.K., Springfield, J., Levitt, M.D. (1998) Fecal hydrogen sulfide production in ulcerative
colitis. Am J Gastroenterol 93, 83–87
|
| |
| 108. |
Farmer, G.W., Vincent, M.M., Fuccillo, D.A., Horta-Barbosa, L., Ritman, S., Sever, J.L., Gitnick, G.L. (1973) Viral investigations
in ulcerative colitis and regional enteritis. Gastroenterology 65, 8–18
|
| |
| 109. |
Wakefield, A.J., Fox, J.D., Sawyerr, A.M., Taylor, J.E., Sweenie, C.H., Smith, M., Emery, V.C., Hudson, M., Tedder, R.S.,
Pounder, R.E. (1992) Detection of herpes-virus DNA in the large intestine of patients with ulcerative colitis and Crohn's
disease using the nested polymerase chain reaction. J Med Virol 38, 183–190
|
| |
| 110. |
Hermon-Taylor, J., Bull, T. (2002) Crohn's disease caused by Mycobacterium avium subspecies paratuberculosis: a public health
tragedy whose resolution is long overdue. J Med Microbiol 51, 3–6
|
| |
| 111. |
van der Wiel-Korstanje, J.A. Winkler, K.C. (1975) The faecal flora in ulcerative colitis. J Med Microbiol 8, 491–501
|
| |
| 112. |
Prindiville, T., Cantrell, M., Wilson, K.H. (2004) Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's
disease. Inflamm Bowel Dis 10, 824–833
|
| |
| 113. |
Sartor, R.B. (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics,
and prebiotics. Gastroenterology 126, 1620– 1633
|
| |
| 114. |
Ricciardiello, L., Baglioni, M., Giovan-nini, C., Pariali, M., Cenacchi, G., Ripalti, A., Landini, M.P., Sawa, H., Nagashima,
K., Frisque, R.J., Goel, A., Boland, C.R. Tognon, M., Roda, E., Bazzoli, F. (2003) Induction of chromosomal instability in
colonic cells by the human polyomavirus JC virus. Cancer Res 63, 7256–7262
|
| |
| 115. |
Ho, G.T., Soranzo, N., Nimmo, E.R., Ten-esa, A., Goldstein, D.B., Satsangi, J. (2006) ABCB1/MDR1 gene determines susceptibility
and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 15, 797–805
|
| |
| 116. |
Newman, B., Gu, X., Wintle, R., Cescon, D., Yazdanpanah, M., Liu, X., Peltekova, V., Van Oene, M., Amos, C.I., Siminovitch,
K.A. (2005) A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's
disease. Gastroenterology 128, 260–269
|
| |
| 117. |
Panwala, C.M., Jones, J.C., Viney, J.L. (1998) A novel model of inflammatory bowel disease: mice deficient for the multiple
drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 161, 5733–5744
|
| |
| 118. |
Papadakis, K.A., Targan, S.R. (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51, 289–298
|
| |
| 119. |
Podolsky, D.K. (2002) Inflammatory bowel disease. N Engl J Med 347, 417–429
|
| |
| 120. |
Karlen, P., Löfberg, R., Brostrom, O., Lei-jonmarck, C.E., Hellers, G., Persson, P.G. (1999) Increased risk of cancer in ulcerative
colitis: a population-based cohort study. Am J Gastroenterol 94, 1047–1052
|
| |
| 121. |
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., Forbes,
A. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126, 451–459
|
| |
| 122. |
Madsen, K.L., Malfair, D., Gray, D., Doyle, J.S., Jewell, L.D., Fedorak, R.N. (1999) Interleukin-10 gene-deficient mice develop
a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 5, 262–270
|
| |
| 123. |
Pullan, R.D., Thomas, G.A., Rhodes, M., Newcombe, R.G., Williams, G.T., Allen, A., Rhodes, J. (1994) Thickness of adherent
mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 35, 353–359
|
| |
| 124. |
Podolsky, D.K., Isselbacher, K.J. (1984) Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis.
Gastroenterology 87, 991–998
|
| |
| 125. |
Rhodes, J.M. (1989) Colonic mucus and mucosal glycoproteins: the key to colitis and cancer? Gut 30, 1660–1666
|
| |
| 126. |
Kim, Y.I. (1998) Short-chain fatty acids in ulcerative colitis. Nutr Rev 56, 17–24
|
| |
| 127. |
Finnie, I.A., Dwarakanath, A.D., Taylor, B.A., Rhodes, J.M. (1995) Colonic mucin synthesis is increased by sodium butyrate.
Gut 36, 93–99
|
| |
| 128. |
Sandborn, W.J. (2003) Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 17, 105–117
|
| |
| 129. |
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura, Y., White, R., Smits, A.M.,
Bos, J.L. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525–532
|
| |
| 130. |
Sato, T., Tanigami, A., Yamakawa, K., Aki-yama, F., Kasumi, F., Sakamoto, G., Naka-mura, Y. (1990) Allelotype of breast cancer:
cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 50, 7184–7189
|
| |
| 131. |
Presti, J.C., Jr. Reuter, V.E., Galan, T., Fair, W.R., Cordon-Cardo, C. (1991) Molecular genetic alterations in superficial
and locally advanced human bladder cancer. Cancer Res 51, 5405–5409
|
| |
| 132. |
Itzkowitz, S.H. (2002) Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 31, 1133– 1144
|
| |
| 133. |
Eaden, J.A., Abrams, K., Ekbom, A., Jackson, E., Mayberry, J. (2000) Colorectal cancer prevention in ulcerative colitis: a
case-control study. Aliment Pharmacol Ther 14, 145–153
|
| |
| 134. |
Pinczowski, D., Ekbom, A., Baron, J., Yuen, J., Adami, H.O. (1994) Risk factors for colorectal cancer in patients with ulcerative
colitis: a case-control study. Gastroenterology 107, 117–120
|
| |
| 135. |
Mathy, C., Schneider, K., Chen, Y.Y., Varma, M., Terdiman, J.P., Mahadevan, U. (2003) Gross versus microscopic pancolitis
and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 9, 351–355
|
| |
| 136. |
Itzkowitz, S.H., Yio, X. (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation.
Am J Physiol Gastrointest Liver Physiol 287, G7–G17
|
| |
| 137. |
Boland, C.R., Thibodeau, S.N., Hamilton, S.R., Sidransky, D., Eshleman, J.R., Burt, R.W., Meltzer, S.J., Rodriguez-Bigas,
M.A., Fodde, R., Ranzani, G.N., Srivastava, S. (1998) A National Cancer Institute Workshop on Microsatellite Instability for
cancer detection and familial predisposition: development of international criteria for the determination of microsatellite
instability in colorectal cancer. Cancer Res 58, 5248– 5257
|
| |
| 138. |
Jass, J.R., Whitehall, V.L., Young, J., Leg-gett, B.A. (2002) Emerging concepts in colorectal neoplasia. Gastroenterology 123, 862–876
|
| |
| 139. |
Willenbucher, R.F., Zelman, S.J., Ferrell, L.D., Moore, D.H., II, Waldman, F.M. (1997) Chromosomal alterations in ulcera-tive
colitis-related neoplastic progression. Gastroenterology 113, 791–801
|
| |
| 140. |
Willenbucher, R.F., Aust, D.E., Chang, C.G., Zelman, S.J., Ferrell, L.D., Moore, D.H., II, Waldman, F.M. (1999) Genomic instability
is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154, 1825–1830
|
| |
| 141. |
Rabinovitch, P.S., Dziadon, S., Brentnall, T.A., Emond, M.J., Crispin, D.A., Haggitt, R.C., Bronner, M.P. (1999) Pancolonic
chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59, 5148–5153
|
| |
| 142. |
Hammarberg, C., Slezak, P., Tribukait, B. (1984) Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA
study. Cancer 53, 291–295
|
| |
| 143. |
Rubin, C., Haggitt, R.C., Burmer, G.C., Brentnall, T.A., Stevens, A.C., Levine, D.S., Dean, P.J., Kimmey, M., Perera, D.R.,
Rab-inovitch, P.S. (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis.
Gas-troenterology 103, 1611–1620
|
| |
| 144. |
O'Sullivan, J.N., Bronner, M.P., Brentnall, T.A., Finley, J.C., Shen, W.T., Emerson, S., Emond, M.J., Gollahon, K.A., Moskovitz,
A.H., Crispin, D.A., Potter, J.D., Rabino-vitch, P.S. (2002) Chromosomal instability in ulcerative colitis is related to telomere
shortening. Nat Genet 32, 280–284
|
| |
| 145. |
Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323–331
|
| |
| 146. |
Burmer, G.C., Rabinovitch, P.S., Haggitt, R.C., Crispin, D.A., Brentnall, T.A., Kolli, V.R., Stevens, A.C., Rubin, C.E. (1992)
Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103, 1602–1610
|
| |
| 147. |
Yin, J., Harpaz, N., Tong, Y., Huang, Y., Laurin, J., Greenwald, B.D., Hontanosas, M., Newkirk, C., Meltzer, S.J. (1993) p53
point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104, 1633–1639
|
| |
| 148. |
Chaubert, P., Benhattar, J., Saraga, E., Costa, J. (1994) K-ras mutations and p53 alterations in neoplastic and nonneoplastic
lesions associated with longstanding ulcera-tive colitis. Am J Pathol 144, 767–775
|
| |
| 149. |
Kern, S.E., Redston, M., Seymour, A.B., Caldas, C., Powell, S.M., Kornacki, S., Kin-zler, K.W. (1994) Molecular genetic profiles
of colitis-associated neoplasms. Gastroenter-ology 107, 420–428
|
| |
| 150. |
Brentnall, T.A., Crispin, D.A., Rabinovitch, P.S., Haggitt, R.C., Rubin, C.E., Stevens, A.C., Burmer, G.C. (1994) Mutations
in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenter-ology 107, 369–378
|
| |
| 151. |
Holzmann, K., Klump, B., Borchard, F., Hsieh, C.J., Kuhn, A., Gaco, V., Gregor, M., Porschen, R. (1998) Comparative analysis
of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 76, 1–6
|
| |
| 152. |
Lashner, B.A., Shapiro, B.D., Husain, A., Goldblum, J.R. (1999) Evaluation of the usefulness of testing for p53 mutations
in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 94, 456–462
|
| |
| 153. |
Harpaz, N., Peck, A.L., Yin, J., Fiel, I., Hon-tanosas, M., Tong, T.R., Laurin, J.N., Abraham, J.M., Greenwald, B.D., Meltzer,
S.J. (1994) p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 25, 1069–1074
|
| |
| 154. |
Greenblatt, M.S., Bennett, W.P., Hollstein, M., Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer
etiology and molecular pathogenesis. Cancer Res 54, 4855–4878
|
| |
| 155. |
Tornaletti, S., Pfeifer, G.P. (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: implications
for mutations in human cancers. Oncogene 10, 1493–1499
|
| |
| 156. |
Aust, D.E., Terdiman, J.P., Willenbucher, R.F., Chang, C.G., Molinaro-Clark, A., Baretton, G.B., Loehrs, U., Waldman, F.M.
(2002) The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 94, 1421–1427
|
| |
| 157. |
Redston, M.S., Papadopoulos, N., Cal-das, C., Kinzler, K.W., Kern, S.E. (1995) Common occurrence of APC and K-ras gene mutations
in the spectrum of colitis-associated neoplasias. Gastroenterology 108, 383–392
|
| |
| 158. |
Tarmin, L., Yin, J., Harpaz, N., Kozam, M., Noordzij, J., Antonio, L.B., Jiang, H.Y., Chan, O., Cymes, K., Meltzer, S.J. (1995)
Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms.
Cancer Res 55, 2035–2038
|
| |
| 159. |
Umetani, N., Sasaki, S., Watanabe, T., Shi-nozaki, M., Matsuda, K., Ishigami, H., Ueda, E., Muto, T. (1999) Genetic alterations
in ulcerative colitis-associated neo-plasia focusing on APC, K-ras gene and microsatellite instability. Jpn J Cancer Res 90, 1081–1087
|
| |
| 160. |
Greenwald, B.D., Harpaz, N., Yin, J., Huang, Y., Tong, Y., Brown, V.L., McDan-iel, T., Newkirk, C., Resau, J.H., Meltzer,
S.J. (1992) Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous
ulcera-tive colitis. Cancer Res 52, 741–745
|
| |
| 161. |
Fogt, F., Vortmeyer, A.O., Goldman, H., Giordano, T.J., Merino, M.J., Zhuang, Z. (1998) Comparison of genetic alterations
in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol 29, 131–136
|
| |
| 162. |
Benedict, W.F., Xu, H.J. Takahashi, R. (1990) The retinoblastoma gene: its role in human malignancies. Cancer Invest 8, 535– 540
|
| |
| 163. |
Carnero, A., Hannon, G.J. (1998) The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 227, 43–55
|
| |
| 164. |
Cairns, P., Thomas, J.P., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Her-ath, J., Jenkins, R., Westra, W., et
al. (1995) Frequency of homozygous deletion at p16/ CDKN2 in primary human tumours. Nat Genet 11, 210–212
|
| |
| 165. |
Hsieh, C.J., Klump, B., Holzmann, K., Bor-chard, F., Gregor, M., Porschen, R. (1998) Hypermethylation of the p16INK4a promoter
in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 58, 3942–3945
|
| |
| 166. |
Meltzer, S.J., Mane, S.M., Wood, P.K., Resau, J.H., Newkirk, C., Terzakis, J.A., Korelitz, B.I., Weinstein, W.M., Needleman,
S.W. (1990) Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain
reaction products. Cancer Res 50, 3627–3630
|
| |
| 167. |
Burmer, G.C., Levine, D.S., Kulander, B.G., Haggitt, R.C., Rubin, C.E., Rabinovitch, P.S. (1990) c-Ki-ras mutations in chronic
ulcerative colitis and sporadic colon carcinoma. Gastroenterology 99, 416–420
|
| |
| 168. |
Bell, S.M., Kelly, S.A., Hoyle, J.A., Lewis, F.A., Taylor, G.R., Thompson, H., Dixon, M.F., Quirke, P. (1991) c-Ki-ras gene
mutations in dysplasia and carcinomas complicating ulcerative colitis. Br J Cancer 64, 174–178
|
| |
| 169. |
Brentnall, T.A., Crispin, D.A., Bronner, M.P., Cherian, S.P., Hueffed, M., Rabino-vitch, P.S., Rubin, C.E., Haggitt, R.C.,
Boland, C.R. (1996) Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 56, 1237–1240
|
| |
| 170. |
Heinen, C.D., Noffsinger, A.E., Belli, J., Straughen, J., Fischer, J., Groden, J., Fenoglio-Preiser, C.M. (1997) Regenerative
lesions in ulcerative colitis are characterized by microsatellite mutation. Genes Chromosomes Cancer 19, 170–175
|
| |
| 171. |
Suzuki, H., Harpaz, N., Tarmin, L., Yin, J., Jiang, H.Y., Bell, J.D., Hontanosas, M., Groisman, G.M., Abraham, J.M., Meltzer,
S.J. (1994) Microsatellite instability in ulcer-ative colitis-associated colorectal dysplasias and cancers. Cancer Res 54, 4841–4844
|
| |
| 172. |
Cawkwell, L., Sutherland, F., Murgatroyd, H., Jarvis, P., Gray, S., Cross, D., Shepherd, N., Day, D., Quirke, P. (2000) Defective
hMSH2/hMLH1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers. Gut 46, 367–369
|
| |
| 173. |
Noffsinger, A., Kretschmer, S., Belli, J., Fogt, F., Fenoglio-Preiser, C. (2000) Mic-rosatellite instability is uncommon in
intestinal mucosa of patients with Crohn's disease. Dig Dis Sci 45, 378–384
|
| |
| 174. |
Pokorny, R.M., Hofmeister, A., Galandiuk, S., Dietz, A.B., Cohen, N.D., Neibergs, H.L. (1997) Crohn's disease and ulcerative
colitis are associated with the DNA repair gene MLH1. Ann Surg 225, 718–723; discussion 723–715
|
| |
| 175. |
Fleisher, A.S., Esteller, M., Harpaz, N., Leytin, A., Rashid, A., Xu, Y., Liang, J., Stine, O.C., Yin, J., Zou, T.T., Abraham,
J.M., Kong, D., Wilson, K.T., James, S.P., Herman, J.G., Meltzer, S.J. (2000) Micro-satellite instability in inflammatory
bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch
repair gene, hMLH1. Cancer Res 60, 4864–4868
|
| |
| 176. |
Souza, R.F., Yin, J., Smolinski, K.N., Zou, T.T., Wang, S., Shi, Y.Q., Rhyu, M.G., Cot-trell, J., Abraham, J.M., Biden, K.,
Simms, L., Leggett, B., Bova, G.S., Frank, T., Powell, S.M., Sugimura, H., Young, J., Harpaz, N., Shimizu, K., Matsubara,
N., Meltzer, S.J. (1997) Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res 57, 2350–2353
|
| |
| 177. |
Souza, R.F., Appel, R., Yin, J., Wang, S., Smolinski, K.N., Abraham, J.M., Zou, T.T., Shi, Y.Q., Lei, J., Cottrell, J., Cymes,
K., Biden, K., Simms, L., Leggett, B., Lynch, P.M., Frazier, M., Powell, S.M., Harpaz, N., Sugimura, H., Young, J., Meltzer,
S.J. (1996) Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 14, 255–257
|
| |
| 178. |
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., Issa, J.P. (1999) CpG island methylator phenotype in color-ectal
cancer. Proc Natl Acad Sci USA 96, 8681–8686
|
| |
| 179. |
Santini, V., Kantarjian, H.M. Issa, J.P. (2001) Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.
Ann Intern Med 134, 573–586
|
| |
| 180. |
Issa, J.P., Ahuja, N., Toyota, M., Bronner, M.P., Brentnall, T.A. (2001) Accelerated age-related CpG island methylation in
ulcer-ative colitis. Cancer Res 61, 3573–3577
|
| |
| 181. |
Sato, F., Harpaz, N., Shibata, D., Xu, Y., Yin, J., Mori, Y., Zou, T.T., Wang, S., Desai, K., Leytin, A., Selaru, F.M., Abraham,
J.M., Meltzer, S.J. (2002) Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis.
Cancer Res 62, 1148–1151
|
| |
| 182. |
Hussain, S.P., Hofseth, L.J., Harris, C.C. (2003) Radical causes of cancer. Nat Rev Cancer 3, 276–285
|
| |
| 183. |
Marnett, L.J. (2000) Oxyradicals and DNA damage. Carcinogenesis 21, 361–370
|
| |
| 184. |
Wang, D., Kreutzer, D.A., Essigmann, J.M. (1998) Mutagenicity and repair of oxidative DNA damage: insights from studies using
defined lesions. Mutat Res 400, 99–115
|
| |
| 185. |
Morgan, W.F., Corcoran, J., Hartmann, A., Kaplan, M.I., Limoli, C.L., Ponnaiya, B. (1998) DNA double-strand breaks, chromosomal
rearrangements, and genomic instability. Mutat Res 404, 125–128
|
| |
| 186. |
Kinouchi, Y., Hiwatashi, N., Chida, M., Nagashima, F., Takagi, S., Maekawa, H., Toyota, T. (1998) Telomere shortening in the
colonic mucosa of patients with ulcera-tive colitis. J Gastroenterol 33, 343–348
|
| |
| 187. |
Artandi, S.E., DePinho, R.A. (2000) A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10, 39–46
|
| |
| 188. |
Cottliar, A., Fundia, A., Boerr, L., Sambuelli, A., Negreira, S., Gil, A., Gomez, J.C., Cho-pita, N., Bernedo, A., Slavutsky,
I. (2000) High frequencies of telomeric associations, chromosome aberrations, and sister chro-matid exchanges in ulcerative
colitis. Am J Gastroenterol 95, 2301–2307
|
| |
| 189. |
Nair, J., Barbin, A., Velic, I., Bartsch, H. (1999) Etheno DNA-base adducts from endogenous reactive species. Mutat Res 424, 59–69
|
| |
| 190. |
Hussain, S.P., Harris, C.C. (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor
suppressor genes. Cancer Res 58, 4023–4037
|
| |
| 191. |
Wink, D.A., Vodovotz, Y., Laval, J., Laval, F., Dewhirst, M.W., Mitchell, J.B. (1998) The multifaceted roles of nitric oxide
in cancer. Carcinogenesis 19, 711–721
|
| |
| 192. |
Cerda, S., Weitzman, S.A. (1997) Influence of oxygen radical injury on DNA methyla-tion. Mutat Res 386, 141–152
|
| |
| 193. |
Gasche, C., Chirtina, C.L., Rhees, J., Goel, A., Boland, C.R. (2001) Oxidative stress increases frameshift mutations in human
colorectal cancer cells. Cancer Res 61, 7444–7448
|
| |
| 194. |
Chang, C.L., Marra, G., Chauhan, D.P., Ha, H.T., Chang, D.K., Ricciardiello, L., Randolph, A., Carethers, J.M., Boland, C.R.
(2002) Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 283, C148–C154
|
| |
| 195. |
Agoff, S.N., Brentnall, T.A., Crispin, D.A., Taylor, S.L., Raaka, S., Haggitt, R.C., Reed, M.W., Afonina, I.A., Rabinovitch,
P.S., Stevens, A.C., Feng, Z., Bronner, M.P. (2000) The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia.
Am J Pathol 157, 737–745
|
| |
| 196. |
Steele, V.E., Hawk, E.T., Viner, J.L., Lubet, R.A. (2003) Mechanisms and applications of non-steroidal anti-inflammatory drugs
in the chemoprevention of cancer. Mutat Res 523–524, 137–144
|
| |
| 197. |
Gupta, R.A., DuBois, R.N., Wallace, M.C. (2002) New avenues for the prevention of colorectal cancer: targeting cyclo-oxygen-ase-2
activity. Best Pract Res Clin Gastroen-terol 16, 945–956
|
| |
| 198. |
Hegazi, R.A., Mady, H.H., Melhem, M.F., Sepulveda, A.R., Mohi, M., Kandil, H.M. (2003) Celecoxib and rofecoxib potentiate
chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis 9, 230–236
|
| |
| 199. |
Bull, A.W. (2003) The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
Arch Pathol Lab Med 127, 1121– 1123
|
| |
| 200. |
Niho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., Noda, T., Sugimura, T., Wakabayashi, K. (2003) Concomitant suppression
of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Cancer Res 63, 6090–6095
|
| |
| 201. |
Landers, C.J., Cohavy, O., Misra, R., Yang, H., Lin, Y.C., Braun, J., Targan, S.R. (2002) Selected loss of tolerance evidenced
by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123, 689–699
|
| |
| 202. |
Stadnicki, A., Colman, R.W. (2003) Experimental models of inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 51, 149–155
|
| |
| 203. |
Kuhn, R., Löhler, J., Rennick, D., Rajew-sky, K., Muller, W. (1993) Interleukin-10-deficient mice develop chronic enterocolitis.
Cell 75, 263–274
|
| |
| 204. |
Mombaerts, P., Mombaerts, E., Grusby, M.J., Glimcher, L.H., Bhan, A.K., Ton-egawa, S. (1993) Spontaneous development of inflammatory
bowel disease in T cell receptor mutant mice. Cell 75, 274–282
|
| |
| 205. |
Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A.C., Horak, I. (1993) Ulcerative colitis-like disease in mice with
a disrupted interleukin-2 gene. Cell 75, 253–261
|
| |
| 206. |
Elson, C.O., Cong, Y., McCracken, V.J., Dimmitt, R.A., Lorenz, R.G., Weaver, C.T. (2005) Experimental models of inflammatory
bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 206, 260–276
|
| |
| 207. |
Strober, W., Fuss, I.J., Ehrhardt, R.O., Neurath, M., Boirivant, M., Ludviksson, B.R. (1998) Mucosal immunoregula-tion and
inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol 48, 453–458
|
| |
| 208. |
Brown, S.J., Miller, A.M., Cowan, P.J., Slavin, J., Connell, W.R., Moore, G.T., Bell, S., Elliott, P.R., Desmond, P.V., d'Apice,
A.J. (2004) Altered immune system gly-cosylation causes colitis in alpha1,2-fucosyl-transferase transgenic mice. Inflamm Bowel Dis 10, 546–556
|
| |
| 209. |
Hollander, G.A., Simpson, S.J., Mizoguchi, E., Nichogiannopoulou, A., She, J., Gutierrez-Ramos, J.C., Bhan, A.K., Burakoff,
S.J., Wang, B., Terhorst, C. (1995) Severe colitis in mice with aberrant thymic selection. Immunity 3, 27–38
|
| |
| 210. |
Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy, R.P., Elson, C.O. (1994) Dextran sulfate sodium-induced
colitis occurs in severe combined immunodeficient mice. Gastroenterology 107, 1643–1652
|
| |
| 211. |
Warren, B.F., Watkins, P.E. (1994) Animal models of inflammatory bowel disease. J Pathol 172, 313–316
|
| |
| 212. |
Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R. (1990) A novel method in the induction of reliable
experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694– 702
|
| |
| 213. |
Cooper, H.S., Murthy, S.N., Shah, R.S., Sedergran, D.J. (1993) Clinicopathologic study of dextran sulfate sodium experimental
murine colitis. Lab Invest 69, 238–249
|
| |
| 214. |
Ohkusa, T., Okayasu, I., Tokoi, S., Araki, A., Ozaki, Y. (1995) Changes in bacterial phagocytosis of macrophages in experimental
ulcerative colitis. Digestion 56, 159–164
|
| |
| 215. |
Seril, D.N., Liao, J., Yang, G.Y., Yang, C.S. (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies
in humans and animal models. Carcinogenesis 24, 353–362
|
| |
| 216. |
Seril, D.N., Liao, J., Ho, K.L., Warsi, A., Yang, C.S., Yang, G.Y. (2002) Dietary iron supplementation enhances DSS-induced
colitis and associated colorectal carcinoma development in mice. Dig Dis Sci 47, 1266– 1278
|
| |
| 217. |
Seril, D.N., Liao, J., Yang, G.-Y., Yang, C.S. (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies
in humans and animal models. Carcinogenesis 24, 353–362
|
| |
| 218. |
Tanaka, T., Kohno, H., Suzuki, R., Hata, K., Sugie, S., Niho, N., Sakano, K., Taka-hashi, M., Wakabayashi, K. (2006) Dextran
sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate
results in development of multiple colonic neoplasms. Int J Cancer 118, 25–34
|
| |
| 219. |
Cooper, H.S., Everley, L., Chang, W.C., Pfeiffer, G., Lee, B., Murthy, S., Clapper, M.L. (2001) The role of mutant Apc in
the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121, 1407– 1416
|
| |
| 220. |
Chang, W.C.C., Renata, A., Clapper, M.L., Zhang, X., Williams, K.L., Spittle, C.S., Li, T., Cooper, H.S. (2007) Loss of p53
enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Car-cinogenesis 28, 2375–2381
|
| |
| 221. |
Fujii, S., Fujimori, T., Kawamata, H., Takeda, J., Kitajima, K., Omotehara, F., Kaihara, T., Kusaka, T., Ichikawa, K., Ohkura,
Y., Ono, Y., Imura, J., Yamaoka, S., Sakamoto, C., Ueda, Y., Chiba, T. (2004) Development of colonic neoplasia in p53 deficient
mice with experimental colitis induced by dextran sulphate sodium. Gut 53, 710–716
|
| |
| 222. |
Kohonen-Corish, M.R., Daniel, J.J., te Riele, H., Buffinton, G.D., Dahlstrom, J.E. (2002) Susceptibility of Msh2-deficient
mice to inflammation-associated colorectal tumors. Cancer Res 62, 2092–2097
|
| |
| 223. |
Liao, J., Seril, D.N., Lu. G.G., Zhang, M., Toyokuni, S., Yang, A.L., Yang, G.Y. (2008) Increased susceptibility of chronic
ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice. Mol Carcinog. 47(8):638–646.
|
| |
| 224. |
Torres, M.I., Gracìa-Martin, M., Fernandez, M.I., Nieto, N., Gil, A., Rios, A. (1999) Experimental colitis induced by trinitroben-zenesulfonic
acid: an ultrastructural and histochemical study. Dig Dis Sci 44, 2523– 2529
|
| |
| 225. |
Neurath, M.F., Fuss, I., Pasparakis, M., Alexopoulou, L., Haralambous, S., Meyer zum Buschenfelde, K.H., Strober, W., Kol-lias,
G. (1997) Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27, 1743–1750
|
| |
| 226. |
Neurath, M.F., Fuss, I., Kelsall, B.L., Stuber, E., Strober, W. (1995) Antibodies to inter-leukin 12 abrogate established
experimental colitis in mice. J Exp Med 182, 1281–1290
|
| |
| 227. |
Camoglio, L., Juffermans, N.P., Peppelen-bosch, M., te Velde, A.A., ten Kate, F.J., van Deventer, S.J., Kopf, M. (2002) Contrasting
roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol 32, 261–269
|
| |
| 228. |
Gao, D., Wagner, A.H., Fankhaenel, S., Stojanovic, T., Schweyer, S., Panzner, S., Hecker, M. (2005) CD40 antisense oligo-nucleotide
inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 54, 70–77
|
| |
| 229. |
Ten Hove, T.Corbaz, A., Amitai, H., Aloni, S., Belzer, I., Graber, P., Drillenburg, P., van Deventer, S.J., Chvatchko, Y.,
Te Velde, A.A. (2001) Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production
in mice. Gastroenterology 121, 1372–1379
|
| |
| 230. |
Hans, W., Schölmerich, J., Gross, V., Falk, W. (2000) Interleukin-12 induced inter-feron-gamma increases inflammation in acute
dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 11, 67–74
|
| |
| 231. |
Stallmach, A., Marth, T., Weiss, B., Wittig, B.M., Hombach, A., Schmidt, C., Neurath, M., Zeitz, M., Zeuzem, S., Abken, H.
(2004) An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's
disease and experimental colitis in vivo. Gut 53, 339–345
|
| |
| 232. |
D'Argenio, G., Cosenza, V., Delle Cave, M., Iovino, P., Delle Valle, N., Lombardi, G., Mazzacca, G. (1996) Butyrate enemas
in experimental colitis and protection against large bowel cancer in a rat model. Gastroen-terology 110, 1727–1734
|
| |
| 233. |
Hibi, T., Ogata, H., Sakuraba, A. (2002) Animal models of inflammatory bowel disease. J Gastroenterol 37, 409–417
|
| |
| 234. |
Barmeyer, C., Harren, M., Schmitz, H., Heinzel-Pleines, U., Mankertz, J., Seidler, U., Horak, I., Wiedenmann, B., Fromm, M.,
Schulzke, J.D. (2004) Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol 286, G244–252
|
| |
| 235. |
Sohn, K.J., Shah, S.A., Reid, S., Choi, M., Carrier, J., Comiskey, M., Terhorst, C., Kim, Y.I. (2001) Molecular genetics of
ulcerative colitis-associated colon cancer in the inter-leukin 2- and beta(2)-microglobulin-defi-cient mouse. Cancer Res 61, 6912–6917
|
| |
| 236. |
Ludviksson, B.R., Gray, B., Strober, W., Ehrhardt, R.O. (1997) Dysregulated intrathymic development in the IL-2-defi-cient
mouse leads to colitis-inducing thy-mocytes. J Immunol 158, 104–111
|
| |
| 237. |
Dresner-Pollak, R., Gelb, N., Rachmilewitz, D., Karmeli, F., Weinreb, M. (2004) Inter-leukin 10-deficient mice develop osteopenia,
decreased bone formation, and mechanical fragility of long bones. Gastroenterology 127, 792–801
|
| |
| 238. |
Berg, D.J., Davidson, N., Kuhn, R., Muller, W., Menon, S., Holland, G., Thompson-Snipes, L., Leach, M.W., Rennick, D. (1996)
Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+)
TH1-like responses. J Clin Invest 98, 1010–1020
|
| |
| 239. |
Sydora, B.C., Tavernini, M.M., Wessler, A., Jewell, L.D., Fedorak, R.N. (2003) Lack of interleukin-10 leads to intestinal
inflammation, independent of the time at which lumi-nal microbial colonization occurs. Inflamm Bowel Dis 9, 87–97
|
| |
| 240. |
Mahler, M., Leiter, E.H. (2002) Genetic and environmental context determines the course of colitis developing in IL-10-defi-cient
mice. Inflamm Bowel Dis 8, 347–355
|
| |
| 241. |
Balish, E., Warner, T. (2002) Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 160, 2253–2257
|
| |
| 242. |
Scheinin, T., Butler, D.M., Salway, F., Scal-lon, B., Feldmann, M. (2003) Validation of the interleukin-10 knockout mouse
model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133, 38–43
|
| |
| 243. |
Steidler, L., Hans, W., Schotte, L., Neir-ynck, S., Obermeier, F., Falk, W., Fiers, W., Remaut, E. (2000) Treatment of murine
colitis by Lactococcus lactis secreting inter-leukin-10. Science 289, 1352–1355
|
| |
| 244. |
Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A. (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19, 683–765
|
| |
| 245. |
Sturlan, S., Oberhuber, G., Beinhauer, B.G., Tichy, B., Kappel, S., Wang, J., Rogy, M.A. (2001) Interleukin-10-deficient mice
and inflammatory bowel disease associated cancer development. Carcinogenesis 22, 665–671
|
| |
| 246. |
Itzkowitz, S.H., Harpaz, N. (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroen-terology 126, 1634–1648
|
| |
| 247. |
Schreiber, S., Fedorak, R.N., Nielsen, O.H., Wild, G., Williams, C.N., Nikolaus, S., Jacyna, M., Lashner, B.A., Gangl, A.,
Rut-geerts, P., Isaacs, K., van Deventer, S.J., Koningsberger, J.C., Cohard, M., LeBeaut, A., Hanauer, S.B. (2000) Safety
and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study
Group. Gastroenterology 119, 1461–1472
|
| |
| 248. |
Fedorak, R.N., Gangl, A., Elson, C.O., Rut-geerts, P., Schreiber, S., Wild, G., Hanauer, S.B., Kilian, A., Cohard, M., LeBeaut,
A., Feagan, B. (2000) Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's
disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119, 1473–1482
|
| |
| 249. |
De Winter, H., Elewaut, D., Turovskaya, O., Huflejt, M., Shimeld, C., Hagenbaugh, A., Binder, S., Takahashi, I., Kronenberg,
M., Cheroutre, H. (2002) Regulation of mucosal immune responses by recombinant interleukin 10 produced by intestinal epithelial
cells in mice. Gastroenterology 122, 1829–1841
|
| |
| 250. |
Nakase, H., Okazaki, K., Tabata, Y., Ozeki, M., Watanabe, N., Ohana, M., Uose, S., Uchida, K., Nishi, T., Mastuura, M., Tamaki,
H., Itoh, T., Kawanami, C., Chiba, T. (2002) New cytokine delivery system using gelatin microspheres containing interleukin-10
for experimental inflammatory bowel disease. J Pharmacol Exp Ther 301, 59–65
|
| |
| 251. |
Lindsay, J.O., Ciesielski, C.J., Scheinin, T., Brennan, F.M., Hodgson, H.J. (2003) Local delivery of adenoviral vectors encoding
murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 52, 981–987
|
| |
| 252. |
Spencer, S.D., Di Marco, F., Hooley, J., Pitts-Meek, S., Bauer, M., Ryan, A.M., Sordat, B., Gibbs, V.C., Aguet, M. (1998)
The orphan receptor CRF2–4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187, 571–578
|
| |
| 253. |
Kobayashi, M., Kweon, M.N., Kuwata, H., Schreiber, R.D., Kiyono, H., Takeda, K., Akira, S. (2003) Toll-like receptor-dependent
production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 111, 1297– 1308
|
| |
| 254. |
Rakoff-Nahoum, S., Hao, L., Medzhitov, R. (2006) Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25, 319–329
|
| |
| 255. |
O'Mahony, L., Feeney, M., O'Halloran, S., Murphy, L., Kiely, B., Fitzgibbon, J., Lee, G., O'Sullivan, G., Shanahan, F., Collins,
J.K. (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15, 1219–1225
|
| |
| 256. |
Hahm, K.B., Im, Y.H., Parks, T.W., Park, S.H., Markowitz, S., Jung, H.Y., Green, J., Kim, S.J. (2001) Loss of transforming
growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49, 190–198
|
| |
| 257. |
Mandelbrot, D.A., McAdam, A.J., Sharpe, A.H. (1999) B7–1 or B7–2 is required to produce the lymphoproliferative phenotype
in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 189, 435–440
|
| |
| 258. |
Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., Strober, W. (2004) TGF-beta 1 plays an important
role in the mechanism of CD4 + CD25 + regulatory T cell activity in both humans and mice. J Immunol 172, 834–842
|
| |
| 259. |
Erdman, S.E., Poutahidis, T., Tomczak, M., Rogers, A.B., Cormier, K., Plank, B., Hor-witz, B.H., Fox, J.G. (2003) CD4 + CD25
+ regulatory T lymphocytes inhibit microbi-ally induced colon cancer in Rag2-deficient mice. Am J Pathol 162, 691–702
|
| |
| 260. |
Engle, S.J., Hoying, J.B., Boivin, G.P., Ormsby, I., Gartside, P.S., Doetschman, T. (1999) Transforming growth factor beta1
suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59, 3379–3386
|
| |
| 261. |
Engle, S.J., Ormsby, I., Pawlowski, S., Boivin, G.P., Croft, J., Balish, E., Doet-schman, T. (2002) Elimination of colon cancer
in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 62, 6362–6366
|
| |
| 262. |
Erdman, S.E., Rao, V.P., Poutahidis, T., Ihrig, M.M., Ge, Z., Feng, Y., Tomczak, M., Rogers, A.B., Horwitz, B.H., Fox, J.G.
(2003) CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63, 6042–6050
|
| |
| 263. |
Mizoguchi, A., Mizoguchi, E., Bhan, A.K. (1999) The critical role of interleukin 4 but not interferon gamma in the pathogenesis
of colitis in T-cell receptor alpha mutant mice. Gastroenterology 116, 320–326
|
| |
| 264. |
Mizoguchi, A., Mizoguchi, E., Smith, R.N., Preffer, F.I., Bhan, A.K. (1997) Suppres-sive role of B cells in chronic colitis
of T cell receptor alpha mutant mice. J Exp Med 186, 1749–1756
|
| |
| 265. |
Kado, S., Uchida, K., Funabashi, H., Iwata, S., Nagata, Y., Ando, M., Onoue, M., Matsuoka, Y., Ohwaki, M., Morotomi, M. (2001)
Intestinal microflora are necessary for development of spontaneous adenocarci-noma of the large intestine in T-cell receptor
beta chain and p53 double-knockout mice. Cancer Res 61, 2395–2398
|
| |
| 266. |
Funabashi, H., Uchida, K., Kado, S., Mat-suoka, Y., Ohwaki, M. (2001) Establishment of a Tcrb and Trp53 genes deficient mouse
strain as an animal model for spontaneous colorectal cancer. Exp Anim 50, 41–47
|
| |
| 267. |
Bjursten, M., Hultgren, O.H., Hultgren Hornquist, E. (2004) Enhanced pro-inflammatory cytokine production in Galphai2-deficient
mice on colitis prone and colitis resistant 129Sv genetic backgrounds. Cell Immunol 228, 77–80
|
| |
| 268. |
Rudolph, U., Finegold, M.J., Rich, S.S., Harriman, G.R., Srinivasan, Y., Brabet, P., Boulay, G., Bradley, A., Birnbaumer,
L. (1995) Ulcerative colitis and adenocarci-noma of the colon in G alpha i2-deficient mice. Nat Genet 10, 143–150
|
| |
| 269. |
Kader, H.A., Tchernev, V.T., Satyaraj, E., Lejnine, S., Kotler, G., Kingsmore, S.F., Patel, D.D. (2005) Protein microarray
analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and
IL-12p40 levels in Crohn's disease and ulcera-tive colitis patients in remission versus active disease. Am J Gastroenterol 100, 414–423
|
| |
| 270. |
Okada, E., Yamazaki, M., Tanabe, M., Takeuchi, T., Nanno, M., Oshima, S., Okamoto, R., Tsuchiya, K., Nakamura, T., Kanai,
T., Hibi, T., Watanabe, M. (2005) IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4 + mucosal T cells
in mice. Am J Physiol Gastrointest Liver Physiol 288, G745–G754
|
| |
| 271. |
Kontoyiannis, D., Pasparakis, M., Pizarro, T.T., Cominelli, F., Kollias, G. (1999) Impaired on/off regulation of TNF biosynthesis
in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387–398
|
| |
| 272. |
Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T., DeWoody, K.L., Schaible, T.F., Rutgeerts,
P.J. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's
Disease cA2 Study Group. N Engl J Med 337, 1029–1035
|
| |
| 273. |
Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A., Podolsky, D.K., Sands, B.E., Braak-man,
T., DeWoody, K.L., Schaible, T.F., van Deventer, S.J. (1999) Infliximab for the treatment of fistulas in patients with Crohn's
disease. N Engl J Med 340, 1398–1405
|
| |
| 274. |
Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C.,
Olson, A., Bao, W., Rutgeerts, P. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541–1549
|
| |
| 275. |
Kollias, G. (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34, 3–6
|
| |
| 276. |
Hammer, R.E., Richardson, J.A., Simmons, W.A., White, A.L., Breban, M., Taurog, J.D. (1995) High prevalence of colorectal
cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J Investig Med 43, 262–268
|
| |
| 277. |
Strober, W., Fuss I., Mannon, P. (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117, 514–521
|
| |
| 278. |
Brandwein, S.L., McCabe, R.P., Cong, Y., Waites, K.B., Ridwan, B.U., Dean, P.A., Ohkusa, T., Birkenmeier, E.H., Sundberg,
J.P., Elson, C.O. (1997) Spontaneously col-itic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the
enteric bacterial flora. J Immunol 159, 44–52
|
| |
| 279. |
Cong, Y., Brandwein, S.L., McCabe, R.P., Lazenby, A., Birkenmeier, E.H., Sundberg, J.P., Elson, C.O. (1998) CD4 + T cells
reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and
ability to transfer disease. J Exp Med 187, 855–864
|
| |
| 280. |
Cong, Y., Weaver, C.T., Lazenby, A., Elson, C.O. (2002) Bacterial-reactive T regulatory cells inhibit pathogenic immune responses
to the enteric flora. J Immunol 169, 6112– 6119
|
| |
| 281. |
Cong, Y., Weaver, C.T., Lazenby, A., Elson, C.O. (2000) Colitis induced by enteric bacterial antigen-specific CD4 + T cells
requires CD40–CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol 165, 2173–2182
|
| |
| 282. |
Targan, S.R., Landers, C.J., Yang, H., Lodes, M.J., Cong, Y., Papadakis, K.A., Vasiliauskas, E., Elson, C.O., Hershberg, R.M.
(2005) Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.
Gastroenterology 128, 2020–2028
|
| |
| 283. |
Robinson, W.H., Fontoura, P., Lee, B.J., de Vegvar, H.E., Tom, J., Pedotti, R., DiGen-naro, C.D., Mitchell, D.J., Fong, D.,
Ho, P.P., Ruiz, P.J., Maverakis, E., Stevens, D.B., Bernard, C.C., Martin, R., Kuchroo, V.K., van Noort, J.M., Genain, C.P.,
Amor, S., Olsson, T., Utz, P.J., Garren, H., Steinman, L. (2003) Protein microarrays guide toler-izing DNA vaccine treatment
of autoimmune encephalomyelitis. Nat Biotechnol 21, 1033–1039
|
| |
| 284. |
Beckwith, J., Cong, Y., Sundberg, J.P., Elson, C.O., Leiter, E.H. (2005) Cdcs1, a major colitogenic locus in mice, regulates
innate and adaptive immune response to enteric bacterial antigens. Gastroenterology 129, 1473–1484
|
| |
| 285. |
Matsumoto, S., Okabe, Y., Setoyama, H., Takayama, K., Ohtsuka, J., Funahashi, H., Imaoka, A., Okada, Y., Umesaki, Y. (1998)
Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43 71–78
|
| |
| 286. |
Kosiewicz, M.M., Nast, C.C., Krishnan, A., Rivera-Nieves, J., Moskaluk, C.A., Mat-sumoto, S., Kozaiwa, K., Cominelli, F. (2001)
Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 107, 695–702
|
| |
| 287. |
Rivera-Nieves, J., Bamias, G., Vidrich, A., Marini, M., Pizarro, T.T., McDuffie, M.J., Moskaluk, C.A., Cohn, S.M., Cominelli,
F. (2003) Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroen-terology 124, 972–982
|
| |
| 288. |
Bamias, G., Martin, C., Mishina, M., Ross, W.G., Rivera-Nieves, J., Marini, M., Com-inelli, F. (2005) Proinflammatory effects
of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterol-ogy 128, 654–666
|
| |
| 289. |
Marini, M., Bamias, G., Rivera-Nieves, J., Moskaluk, C.A., Hoang, S.B., Ross, W.G., Pizarro, T.T., Cominelli, F. (2003) TNF-alpha
neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis.
Proc Natl Acad Sci USA 100, 8366–8371
|
| |
| 290. |
Matsumoto, S., Watanabe, N., Imaoka, A., Okabe, Y. (2001) Preventive effects of Bifi-dobacterium- and Lactobacillus-fermented
milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion 64, 92–99
|
| |
| 291. |
Croog, V.J., Ulman, T.A., Itzkowitz, S.H. (2003) Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 18, 392–400
|
| |
| 292. |
Velayos, F.S., Terdiman, J.P., Walsh, J.M. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk:
a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100, 1345–1353
|
| |
| 293. |
McKenzie, S.M., Doe, W.F., Buffinton, G.D. (1999) 5-aminosalicylic acid prevents oxidant mediated damage of glyceralde-hyde-3-phosphate
dehydrogenase in colon epithelial cells. Gut 44, 180–185
|
| |
| 294. |
Bus, P.J., Nagtegaal, I.D., Verspaget, H.W., Lamers, C.B., Geldof, H., Van Krieken, J.H., Griffioen, G. (1999) Mesalazine-induced
apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13, 1397–1402
|
| |
| 295. |
Nosal'ova, V., Cerna, S., Bauer, V. (2000) Effect of N-acetylcysteine on colitis induced by acetic acid in rats. Gen Pharmacol 35, 77–81
|
| |
| 296. |
Ardite, E., Sans, M., Panes, J., Romero, F.J., Pique, J.M., Fernandez-Checa, J.C. (2000) Replenishment of glutathione levels
improves mucosal function in experimental acute colitis. Lab Invest 80, 735–744
|
| |
| 297. |
Seril, D.N., Liao, J., Ho, K.L., Yang, C.S., Yang, G.Y. (2002) Inhibition of chronic ulcerative colitis-associated colorectal
aden-ocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 23, 993–1001
|
| |
| 298. |
Graf, E., Eaton, J.W. (1985) Dietary suppression of colonic cancer. Fiber or phytate? Cancer 56, 717–718
|
| |
| 299. |
Liao, J., Seril, D.N., Yang, A.L., Lu, G.G., Yang, G.Y. (2007) Inhibition of chronic ulcerative colitis associated adenocarcinoma
development in mice by inositol compounds. Carcinogenesis 28, 446–454
|
| |
| 300. |
Shamsuddin, A.M., Elsayed, A.M., and Ullah, A. (1988) Suppression of large intestinal cancer in F344 rats by inositol hexa-phosphate.
Carcinogenesis 9, 577–580
|
| |
| 301. |
Ullah, A., Shamsuddin, A.M. (1990) Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344
rats. Carcinogenesis 11, 2219–2222
|
| |
| 302. |
Reddy, B.S. (1999) Prevention of colon car-cinogenesis by components of dietary fiber. Anticancer Res 19, 3681–3683
|
| |
| 303. |
Shamsuddin, A.M., Ullah, A. (1989) Inosi-tol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction
by azoxymethane. Carcinogenesis 10, 625–626
|
| |
| 304. |
Thompson, L.U., Zhang, L. (1991) Phytic acid and minerals: effect on early markers of risk for mammary and colon carcinogenesis.
Carcinogenesis 12, 2041–2045
|
| |
| 305. |
Reddy, B.S. (1999) Role of dietary fiber in colon cancer: an overview. Am J Med 106, 16S–19S; discussion 50S–51S
|
| |
| 306. |
Shamsuddin, A.M., Ullah, A., and Chakra-varthy, A.K. (1989) Inositol and inositol hexaphosphate suppress cell proliferation
and tumor formation in CD-1 mice. Car-cinogenesis 10, 1461–1463
|
| |
| 307. |
Vucenik, I., Yang, G.Y., Shamsuddin, A.M. (1997) Comparison of pure inositol hexa-phosphate and high-bran diet in the prevention
of DMBA-induced rat mammary carcinogenesis. Nutr Cancer 28, 7–13
|
| |
| 308. |
Vucenik, I., Yang, G.Y., Shamsuddin, A.M. (1995) Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer.
Carcinogenesis 16, 1055–1058
|
| |
| 309. |
Vucenik, I., Sakamoto, K., Bansal, M., Shamsuddin, A.M. (1993) Inhibition of rat mammary carcinogenesis by inositol hexa-phosphate
(phytic acid). A pilot study. Cancer Lett 75, 95–102
|
| |
| 310. |
Lee, H.J., Lee, S.A., Choi, H. (2005) Dietary administration of inositol and/or inositol-6-phosphate prevents chemically-induced
rat hepatocarcinogenesis. Asian Pac J Cancer Prev 6, 41–47
|
| |
| 311. |
Vucenik, I., Zhang, Z.S., Shamsuddin, A.M. (1998) IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses
pre-existing human liver cancer xenotrans-planted in nude mice. Anticancer Res 18, 4091–4096
|
| |
| 312. |
Vucenik, I., Tantivejkul, K., Zhang, Z.S., Cole, K.E., Saied, I., Shamsuddin, A.M. (1998) IP6 in treatment of liver cancer.
I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18, 4083–4090
|
| |
| 313. |
Wattenberg, L.W. (1999) Chemopreven-tion of pulmonary carcinogenesis by myo-inositol. Anticancer Res 19, 3659–3661
|
| |
| 314. |
Gupta, K.P., Singh, J., Bharathi, R. (2003) Suppression of DMBA-induced mouse skin tumor development by inositol hexaphosphate
and its mode of action. Nutr Cancer 46, 66–72
|
| |
| 315. |
Ishikawa, T., Nakatsuru, Y., Zarkovic, M., Shamsuddin, A.M. (1999) Inhibition of skin cancer by IP6 in vivo: initiation-promotion
model. Anticancer Res 19, 3749–3752
|
| |
| 316. |
Singh, R.P., Agarwal, R. (2005) Prostate cancer and inositol hexaphosphate: efficacy and mechanisms. Anticancer Res 25, 2891– 2903
|
| |
| 317. |
Sharma, G., Singh, R.P., Agarwal, R. (2003) Growth inhibitory and apoptotic effects of inositol hexaphosphate in transgenic
adeno-carcinoma of mouse prostate (TRAMP-C1) cells. Int J Oncol 23, 1413–1418
|
| |
| 318. |
Vucenik, I., Tomazic, V.J., Fabian, D., Shamsuddin, A.M. (1992) Antitumor activity of phytic acid (inositol hexaphosphate)
in murine transplanted and metastatic fibrosar-coma, a pilot study. Cancer Lett 65, 9–13
|
| |
| 319. |
Vucenik, I., Kalebic, T., Tantivejkul, K., Shamsuddin, A.M. (1998) Novel antican-cer function of inositol hexaphosphate: inhibition
of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 18, 1377–1384
|
| |